Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies.

ABSTRACT: The recent discoveries of broadly potent neutralizing human monoclonal antibodies represent a new generation of antiretrovirals for the treatment and prophylaxis. Antibodies are generally considered more effective and safer and have been proved to provide passive protection against mucosal challenge in humanized mice and macaques. Several neutralizing Abs could protect animals against HIV-1 but are not effective when used in an established infected model for therapy. In order to overcome the limitation of antiviral activities, multiple antibody-engineering technologies have been explored to generate "the better" neutralizing antibodies against HIV-1 since bNAbs attack viral entry by various mechanisms. Thus, a promising direction of research is to discover and exploit rational antibody com

SUBMITTER: Sun M 

PROVIDER: S-EPMC5043134 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature